Breaking News
September 25, 2018 - Antibiotics best paediatric treatment for children’s chronic wet cough
September 25, 2018 - Looking beyond opioids: Stanford pain psychologist briefs Congress
September 25, 2018 - Organs actively fighting back against autoimmune diseases, finds study
September 25, 2018 - Lancaster professor aims to understand how genes affect smoking cessation
September 25, 2018 - Human-oriented perspective needed to better understand Parkinson’s disease
September 25, 2018 - Physical activity may have beneficial effects for people with rare Alzheimer’s disease
September 25, 2018 - FDA Updates on Valsartan Recalls
September 25, 2018 - 3-D-printed tracheal splints used in groundbreaking pediatric surgery
September 25, 2018 - Who is the designated driver, or proxy, for your health decisions?
September 25, 2018 - New chemo-optogenetic method enables multi-directional activity control of cellular processes
September 25, 2018 - Study explores link between genetic predisposition to Alzheimer’s and cardiometabolic risk factors
September 25, 2018 - NeoTract presents new clinical data from studies of UroLift System for patients with BPH
September 25, 2018 - Statins Improve Long-Term Survival After AAA Repair
September 25, 2018 - Novel brain network linked to chronic pain in Parkinson’s disease
September 25, 2018 - Researchers reassess negative pressure wound therapy as its benefit and harm remain unclear
September 25, 2018 - Older adults with ‘fall plan of care’ less likely to suffer fall-related hospitalizations
September 25, 2018 - FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials
September 25, 2018 - IME Medical Electrospinning establishes state-of-the-art manufacturing lab facilities
September 25, 2018 - Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results
September 25, 2018 - How to Protect Your Eyesight
September 25, 2018 - Novel approach allows researchers to define how cells in the retina respond to diabetes
September 25, 2018 - Columbia University announces winners of 2018 Louisa Gross Horwitz Prize
September 25, 2018 - Clinical trial investigators found non-compliant with requirement to report results on EU register
September 25, 2018 - Study analyzes quality of protein supplements in function of source, treatment and storage
September 25, 2018 - FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome
September 25, 2018 - U.S. Alzheimer’s Cases to Nearly Triple by 2060
September 25, 2018 - Improving cell replacement therapy for Parkinson’s disease
September 25, 2018 - Genervon reports new findings that drug candidate GM6 attenuates Alzheimer’s disease in mice model
September 25, 2018 - FDA approves new 5 mm diameter drug-eluting stent from Cook Medical
September 25, 2018 - New $17.8 million grant ensures USC at forefront of research on tobacco-related health risks
September 25, 2018 - Researchers analyze response to combination immunotherapy for patients with rare skin cancer
September 25, 2018 - Study sheds light on how brain protein may be involved neurodevelopmental disorders
September 25, 2018 - Where to draw the line on incentives
September 25, 2018 - Solid fuel use linked with increased risk of hospitalization or death from respiratory diseases
September 25, 2018 - ‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms
September 25, 2018 - Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE
September 25, 2018 - Global leaders must make bold commitments at first-ever UN tuberculosis summit
September 25, 2018 - Brief sleep intervention works long-term to prevent child obesity
September 25, 2018 - Vaping among kids and teens a growing concern
September 25, 2018 - Public launch of products and application solutions from Porvair Laboratory Division
September 25, 2018 - Harmful H. pylori may play a role in Parkinson’s disease
September 25, 2018 - Researchers develop way to measure different types of fear of falling in patients with Parkinson’s
September 25, 2018 - Fracture causes bone density losses throughout the body
September 25, 2018 - Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder
September 25, 2018 - Hybrid theranostic complex shows high therapeutic efficacy against tumor cells
September 25, 2018 - FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
September 25, 2018 - Toxicological evaluation and dosimetry estimation of potential PET radiotracer
September 25, 2018 - 5 obstacles parents commonly face in child obesity treatment and how to overcome them
September 25, 2018 - Immunologist to study how Chikungunya causes devastating effects in older adults
September 25, 2018 - Rural borderland communities vulnerable to high stress impacting mental and physical health
September 25, 2018 - SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship
September 25, 2018 - Common painkiller not effective in controlling chronic pain after traumatic nerve injury
September 25, 2018 - New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer
September 25, 2018 - Environmentally-induced gene activity influences IQ test performance
September 25, 2018 - Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI
September 25, 2018 - FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
September 25, 2018 - Medical device company settles US case over false claims
September 25, 2018 - Trying to get answers: One woman’s quest for a diagnosis
September 25, 2018 - Lung cancer patients treated with invasive surgery more likely to become chronic opioid users
September 25, 2018 - Oxford VR raises £3.2m to boost innovation in VR for mental health problems
September 25, 2018 - Gene therapy approach could help treat mitochondrial diseases
September 25, 2018 - Few Yogurt Products Qualify As Low-Sugar
September 25, 2018 - Eye disease can cause blindness, and it’s on the rise
September 25, 2018 - Pawnshop density linked to gun-related suicides, Stanford study finds
September 25, 2018 - Pioneering procedure for common prostate condition offered by The London Clinic
September 25, 2018 - Number of people with respiratory diseases likely to increase if UK air pollution remains unchecked
September 25, 2018 - FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
Esketamine Nasal Spray Eases Depression Quickly

Esketamine Nasal Spray Eases Depression Quickly

image_pdfDownload PDFimage_print

Action Points

  • Note that this small randomized trial demonstrated that an intranasal formulation of the s-enantiomer of ketamine had strong anti-depressant effects compared to placebo.
  • Be aware that individuals with psychotic symptoms or a history of psychosis were excluded as the drug could potentiate these symptoms.

An intranasal formulation of ketamine quickly diminished depressive symptoms in patients with treatment-resistant depression, researchers found.

In a phase II study, those taking one of three doses of esketamine (28 mg, 56 mg, or 84 mg) had significantly greater improvement in Montgomery-Asberg Depression Rating Scale (MADRS) scores compared with placebo over 8 days, Ella Daly, MD, of Janssen, and colleagues reported online in JAMA Psychiatry.

Those improvements persisted despite reduced dosing frequency in a subsequent open-label phase that lasted about two months, the researchers said.

Several studies have shown ketamine to have antidepressant effects, and there’s been growing interest in this and other NMDA receptor antagonists, in the class of glutamate receptor modulators, to treat depression and suicidality — especially since about a third of patients don’t respond to current treatment options.

A limitation of ketamine, however, is that it needs to be delivered intravenously. So researchers at Janssen developed an intranasal formulation called esketamine, which is the S-enantiomer of ketamine. This version has a higher affinity for the NMDA receptor than the ketamine R-enantiomer, the researchers explained, adding that nasal delivery will also boost bioavailability of the compound. (The chirally pure molecule can also be patented separately from the racemic form.)

The current study enrolled patients at multiple outpatient referral centers from January 2014 to September 2015. It involved four phases: screening; double-blind treatment (days 1-15) composed of two one-week periods; optional open-label treatment (days 15-74); and post-treatment follow-up (8 weeks).

This design allowed for a smaller sample size to assess efficacy, dose-response, and safety than a standard parallel-group design, while preserving a low chance of type 2 error to avoid missing the efficacy signal, the researchers said.

A total of 67 patients (mean age 45) were randomized, and 60 completed both double-blind periods. All had treatment-resistant depression, which was defined as a lack of clinically meaningful improvement after treatment with at least two different oral antidepressants taken at adequate doses. All of them continued to take their oral antidepressants during the study, and esketamine nasal spray was delivered under the supervision of a healthcare professional.

In the first period, participants were randomized to placebo or to one of the three doses of esketamine. In the second phase, 28 placebo-treated patients with moderate-to-severe symptoms were re-randomized to one of the four treatment arms, while those with mild symptoms continued to receive placebo. Finally, during the open-label phase, dosing frequency was reduced from twice weekly to weekly, then to every two weeks.

The primary efficacy endpoint was change from baseline to 8 days on the MADRS scale.

Overall, Daly and colleagues found that the anti-depressant effect was rapid in onset, evident as early as two hours post-dose, and was dose-related. Mean MADRS scores fell in all groups, with significantly greater improvement in all esketamine dose groups compared with placebo, as well as a dose-response relationship.

  • 28 mg: −4.2, P=0.02
  • 56 mg: −6.3, P=0.001
  • 84 mg: −9.0, P<0.001

These improvements persisted over 8 weeks of follow-up without additional esketamine doses in those who remained in the study, the researchers added. Responses “appeared to persist for more than two months with a lower dosing frequency,” they wrote.

During the double-blind phase, the most common treatment-emergent adverse events in esketamine-treated patients were dizziness, headache, and dissociative symptoms. (The latter has been a problem with racemic ketamine; the quasi-hallucinatory effect has made it a drug of abuse, with street names such as Special K.)

Three of 56 esketamine-treated patients discontinued the study during the blinded phase, as did one of 57 patients during the open-label phase. These included one event each of syncope, headache, dissociative syndrome, and ectopic pregnancy. None of the placebo-treated patients discontinued.

Most esketamine-treated patients had transient elevations in blood pressure and heart rate on dosing days, which returned to normal within two hours of the dose. Perceptual changes or dissociative symptoms began shortly after the start of intranasal dosing, peaked at 30 to 40 minutes, and similarly resolved by two hours. These effects attenuated in all dose groups with repeated dosing, and there was no psychosis.

Daly and colleagues concluded that the results support further investigation in larger trials, and the drug is currently being evaluated in phase III trials in treatment-resistant depression and for patients with major depressive disorder who are at immediate risk for suicide.

In an accompanying editorial, Ole Andreassen, MD, PhD, of Oslo University, and colleagues said the significant effects at just one week are “substantially faster than current treatments.”

While esketamine is a good candidate for intranasal delivery, they wrote, some potential barriers include mucosal inflammation, nasal polyps, and septal deviation. Poor self-administration practices can also reduce efficacy, they noted.

Although there was no psychosis in the trial, patients with psychotic disorders or major depressive disorder with psychosis were excluded, Andreassen and colleagues cautioned. They also urged that “the potential for addiction” be evaluated in future studies.

Still, they said the results demonstrate “considerable promise of combining a compound with rapid antidepressant effects with intranasal delivery” and await results from phase III results.

Several authors are employees of Janssen, which funded the study.

The editorialists disclosed financial relationships with Lundbeck and being co-inventors on an intranasal oxytocin delivery device.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-28T16:30:00-0500

Tagged with:

About author

Related Articles